Former New Orleans Saints first-round draft pick Sheldon Rankins was trying to make a playoff push with his new team, but will now be lost for the remainder of the year due to a weekslong illness.

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugmaker Eisai.